Energy & Environmental Law Adviser
Product Liability & Mass Torts Blog
Employment Law Landscape
Joel M. Wallace works primarily in intellectual property litigation, with significant experience in patent and trademark litigation and non-litigation analyses across a range of industries including pharmaceuticals, medical devices and consumer goods and services. As part of his practice, he regularly prepares Hatch-Waxman Paragraph IV letters, advises clients on patent and regulatory issues, and advocates for clients in litigation, including fact discovery, expert discovery, trial, and appeal. Joel also has experience in post-grant review practice before the PTO, including preparation of petitions for inter partes review.
Prior to joining Schiff Hardin, Joel was an associate in the Chicago office of an international law firm.
Joel also participated in the following patent litigation matters prior to joining Schiff Hardin:
Pfizer’s recent decision not to disclose data about Enbrel’s potential to treat Alzheimer’s disease has caused much debate about drugmakers’ obligations to the public.
Center for Biosimilars
As the government shutdown stretches on, pharmaceutical companies must manage the partial shutdown of the U.S. Food and Drug Administration (FDA).
Schiff Hardin is pleased to announce that 10 attorneys have been elected to its partnership, effective January 1, 2019.
Schiff Hardin successfully secured a favorable outcome for our client, Fresenius Kabi USA LLC, in a patent-infringement suit filed by Hospira Inc., which paves the way for Fresenius to market a new generic drug.
The Center for Biosimilars
In the quick pound of a gavel, the entire U.S. pharmaceutical and biologics industries were thrown into doubt after Judge Reed O’Connor of the United States District Court for the Northern District of Texas found the individual mandate of the Affordable Care Act (ACA) – and therefore the entire act – unconstitutional.
Today’s oral arguments in Supreme Court case Helsinn Healthcare v. Teva illustrate the power that a successful appeal could have to change a longstanding doctrine and significantly impact how businesses handle intellectual property transactions.
Joel represented plaintiffs in a putative class action suit regarding the issuance of immigration detainers against foreign-born U.S. citizens or legal permanent residents without investigation.
As demonstrated by the California Supreme Court's recent Cipro reverse payment decision, Actavis' ʺrule of reasonʺ is not just guiding federal courts anymore.